Crossmark

Renoprotection with SGLT2 inhibitors in type 2 diabetes over a spectrum of cardiovascular and renal risk

Published Online: 2020-11-22

Published Print: 2020-12

Authors

Giorgino, Francesco http://orcid.org/0000-0001-7372-2678
Vora, Jiten

Fenici, Peter

Solini, Anna
Funding

Funding for this research was provided by:

AstraZeneca
License Information

Text and Data Mining valid from 2020-11-22

Version of Record valid from 2020-11-22
More Information

Article History

Received: 4 August 2020

Accepted: 29 October 2020

First Online: 22 November 2020

Ethics approval and consent to participate

: Not applicable.

: Not applicable.

: FG has received research support from Eli Lilly, Lifescan, and Takeda, and consultant fees from AstraZeneca, Boehringer-Ingelheim, Eli Lilly, Merck Sharp and Dohme, NovoNordisk, Roche Diabetes Care, and Sanofi. JV was a contractor acting as Chief Medical Advisor for cardiovascular, renal, and metabolic diseases at AstraZeneca at the time of manuscript development. PF is an employee of AstraZeneca. AS has received research grants from AstraZeneca and advisory board and speaker’s fees from AstraZeneca, Boehringer Ingelheim, Lilly, Mundipharma, NovoNordisk, and Sanofi.

Document is current